115 related articles for article (PubMed ID: 21592000)
21. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
[TBL] [Abstract][Full Text] [Related]
22. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
23. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
Muñoz M; Coveñas R
Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
[TBL] [Abstract][Full Text] [Related]
24. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.
Lindström E; von Mentzer B; Påhlman I; Ahlstedt I; Uvebrant A; Kristensson E; Martinsson R; Novén A; de Verdier J; Vauquelin G
J Pharmacol Exp Ther; 2007 Sep; 322(3):1286-93. PubMed ID: 17575073
[TBL] [Abstract][Full Text] [Related]
25. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
26. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
27. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
28. Activation of neurokinin-1 receptor by substance P inhibits melanogenesis in B16-F10 melanoma cells.
Ping F; Shang J; Zhou J; Song J; Zhang L
Int J Biochem Cell Biol; 2012 Dec; 44(12):2342-8. PubMed ID: 23041339
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD
Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886
[TBL] [Abstract][Full Text] [Related]
30. A new frontier in the treatment of cancer: NK-1 receptor antagonists.
Muñoz M; Rosso M; Coveñas R
Curr Med Chem; 2010; 17(6):504-16. PubMed ID: 20015033
[TBL] [Abstract][Full Text] [Related]
31. NK-1 receptor antagonists: a new generation of anticancer drugs.
Munoz M; Covenas R
Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565
[TBL] [Abstract][Full Text] [Related]
32. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
33. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
Jordan K
Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.
Gether U; Emonds-Alt X; Brelière JC; Fujii T; Hagiwara D; Pradier L; Garret C; Johansen TE; Schwartz TW
Mol Pharmacol; 1994 Mar; 45(3):500-8. PubMed ID: 8145735
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
Rizzi A; Campi B; Camarda V; Molinari S; Cantoreggi S; Regoli D; Pietra C; Calo' G
Peptides; 2012 Sep; 37(1):86-97. PubMed ID: 22732666
[TBL] [Abstract][Full Text] [Related]
36. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
37. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
38. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
